The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Bayer expects 2025 to be the most difficult year of its turnaround
Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
The 27 greenfield labs across the country ensure timely and accurate reporting
Subscribe To Our Newsletter & Stay Updated
